To the Editor:
In April 2023, Annabel et al report a national prevalence of SARS-CoV-2
antibodies in primary and secondary school children in England [1].
They found high seroprevalence rate of SARS-CoV-2 either in primary or
secondary school students. In particular, approximately three fold
higher than confirmed infections in unvaccinated children. In late 2022,
coronavirus disease 2019 (COVID-19) caused by Omicron variants of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swept away rapidly
throughout China, especially in Guangdong Province (~two
weeks). Considering the high coverage of COVID-19 vaccines in China
[2], the prevention strategies of COVID-19 had been changed from
whole population-wide to key and high-risk population [3].
The archived data of COVID-19 vaccine has proved its safety and
effectiveness, and has significant effects on preventing virus
transmission, reducing disease and death. However, the immune protection
effects of vaccination are less durable. The emerging variants of
SARS-CoV-2 showed stronger immune escape and transmission ability, and
the breakthrough and second infection of COVID-19 have become the
biggest challenge for public. This study was designed to investigate the
neutralizing antibody (NAb) levels of individuals after first wave
rapidly pandemic and the second wave sporadic infection since the end of
2022, and aim to evaluate the cross protection against the latest
circulated variants of SARS-CoV-2 in China.
From December 2022 to January 2023, each serum samples was collected
from 107 public health workers (adults) at Guangdong Provincial Center
for Disease Control and Prevention (GDCDC) who had recovered 4 weeks of
first wave COVID-19 pandemic caused by Omicron BA.5 [4]. All
participants aged between 22 and 62, including 44 males and 63 females.
In July 2023, during the second wave of COVID-19 epidemic caused by
Omicron XBB.1.9 in Guangdong Province, 10 (aged 31-57 years old, 10
females) participants reported first or secondary infection, each serum
sample were collected accordingly.
The neutralization assay against to SARS-CoV-2 was performed in a
biosafety third-level laboratory (BSL-3) of GDCDC. Prototype
(2020XN4276) and Omicron sub-lineages (BA.5, GDPCC 2.00303; BQ.1, GDPCC
2.01502; XBB.1.1, GDPCC 2.01503; XBB.1.9, GDPCC 2.01543; XBB.1.16, GDPCC
2.01541) of SARS-CoV-2 clinical isolates were used as target virus, and
the titer of each serum sample was determined according to the standard
protocol as previously described [5].
For the serum samples from first wave infection participants, we found
the NAb titers were significantly decreased against prototype SARS-CoV-2
compared to Omicron variants BA.5, BQ.1 and XBB.1.1. The highest
geometric mean titer (GMT) of the samples against prototype was 280, and
the GMT for BA.5 was 41 (5.79 fold, P<0.001), BQ.1 and XBB 1.1
was only 8 (BQ.1, 35.86 fold, P<0.001; XBB.1.1, 32.67 fold,
P<0.001) (Figure 1A). To investigate the differences in
antibody levels among populations with different immunization history,
the collected serum samples from first wave infection were divided into
three groups, including the primary, the homologous booster and the
heterologous booster vaccination group. The GMT in all three groups was
higher against prototype than that for BA.5, BQ.1 and XBB.1.1 (Figure
1B-D). In the primary vaccination group, only one serum sample had a
higher titer of neutralizing antibodies against BQ.1 than BA.5. The GMT
dropped from 152 for prototype to 38 for BA.5 (2.99 fold, P=0.343), 11
for BQ.1 (12.44 fold, P=0.08) and 8 for XBB.1.1 (18.00 fold,
P<0.05) (Figure 1B). In the homologous booster vaccination
group, the GMT dropped from 286 for prototype to 45 for BA.5 (5.41 fold,
P<0.001), 8 for BQ.1 (36.55 fold, P<0.001) and
XBB.1.1 (33.53 fold, P<0.001) (Figure 1C). In the heterologous
booster vaccination group, the GMT dropped from 287 for prototype, to 22
for BA.5 (11.68 fold, P<0.001), 6 for BQ.1 (44.20 fold,
P<0.001), and 8 for XBB.1.1 (32.86 fold, P<0.001)
(Figure 1D). In particular, participants from the homologous booster
vaccination group had the same titers of neutralizing antibodies against
BA.5 and BQ.1.
In addition, the IgG antibody of serum was detected using a commercial
SARS-CoV-2 IgG antibody (Magnetic particle chemiluminescence method)
test kit (Autobio, Ltd., Co., Shanghai, China). The positive rate of IgG
antibody was 98.13% (105/107) (Supplementary Table 1). The median of
IgG antibody in homologous booster vaccination group was the highest, at
131.52, followed with the heterologous booster vaccination group, with a
median of 127.91 and the primary vacancy group, with 79.72 only (Table
1). There was no correlation between IgG antibody level and the GMT
against the prototype virus (r=0.016, P=0.867).
However, for the serum samples from second wave infection participants,
we found the highest geometric mean titer (GMT) of the samples against
prototype was 362, and the GMT for BA.5 was 119 (2.03 fold,
P<0.01), XBB.1.16 was 79 and XBB.1.9 was 69 (XBB.1.16, 3.59
fold, P<0.01; XBB.1.9, 4.28 fold, P<0.01)
(Supplementary Figure 1A). The IgG antibody of all participants were
detected as positive (10/10), the median of IgG antibody was 235.09
(Supplementary Table 1 and Supplementary Figure 1B).
In summary, we identified the NAb titer of against prototype and Omicron
variants BA.5 were significantly higher than that against Omicron
variants BQ.1, XBB.1.1, XBB.1.9 and XBB.1.16 whether primary or
secondary infection. The cross protection of neutralizing antibodies
induced by prototype and Omicron BA.5 were poor when challenged by BQ.1,
XBB.1.1, XBB.1.9 and XBB.1.16 variants, indicating that we should pay
attention to the risk of multiple infection of any other novel Omicron
variants emerging in near future.